Elanco Raises 2026 Revenue and EPS Guidance Following Strong Q3 Performance
Elanco Animal Health (ELAN) has raised its full-year 2026 financial outlook following a strong third quarter. The company reported revenue growth of 11% on a reported basis, representing 9% organic growth in constant currency, exceeding management's previous commitments. The updated guidance projects 2026 revenue to reach between $5.155 billion and $5.18 billion, with adjusted earnings per share (EPS) expected to fall between $1.17 and $1.20. Additionally, the company is targeting a net leverage ratio of approximately 2.9x as it continues its financial management strategy.
Tickers: $ELAN